Low dose-CT for differentiation between AECOPD and pneumonia. An effective tool for diagnosis?

Low dose-CT for differentiation between AECOPD and pneumonia. An effective tool for diagnosis? - Maastricht COPD CT study (MCCT)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44303

Enrollment

202

Registered

2015-03-25

Start date

2016-02-29

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute exacerbation COPD acute lungattack COPD

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Adults, either sex, older than 40 years of age; • Smoking history of 10 Pack Years or more; • Diagnosis of COPD stages I-IV, class A-D, as defined by the Global initiative for chronic Obstructive Lung Disease (GOLD); • Doctor*s diagnosis of AECOPD (clinical presentation of a patient complaining of an acute change of symptoms that is beyond normal day-to-day variation - baseline dyspnoea, cough and/or sputum production); • Patients must sign and date an informed consent prior to inclusion in the study.

Exclusion criteria

Exclusion criteria: • Progressively fatal disease, or life expectancy

Design outcomes

Primary

Measure	Time frame
To determine the true prevalence of pneumonia in exacerbating COPD patients as analysed by low dose-CT	—

Secondary

Measure	Time frame
- To determine clinical and/or biochemical predictors (PCT) for pneumonia in COPD patients proven by low dose-CT; - To describe additional pulmonary pathology evidenced by low dose-CT; - Phenotype COPD exacerbations based on outcomes of low dose-CT (standardized assessment).	—

Countries

Netherlands

Outcome results